New liquid thyroid drug tested in infants: could it be better?

NCT ID NCT06724224

Recruiting now Disease control Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at three forms of levothyroxine (a thyroid hormone medicine) given to babies diagnosed with congenital hypothyroidism. Researchers will compare a new oral solution to standard liquid drops and tablets, checking how well they control hormone levels and affect development. The goal is to see if the new formulation is safer and more effective in the medium to long term.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: levothyroxine (thyroid hormone replacement)
What this could lead to: If successful, this could show that a new liquid form of levothyroxine works as well or better than current options, potentially improving treatment for babies with congenital hypothyroidism.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It is also small (120 participants) and limited to one region in Italy, so findings may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL HYPOTHYROIDISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital hypothyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL HYPOTHYROIDISM

Contacts and locations

Locations

IRCCS Azienda Ospedaliero-Universitaria di Bologna
RECRUITING

Bologna, Bologna, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.